Literature DB >> 2479963

Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party.

.   

Abstract

Two policies of treatment for small-cell lung cancer, both of which have their advocates in the United Kingdom, have been compared in a randomised multicentre study. Of a total of 151 patients, 76 were allocated to immediate combination chemotherapy and radiotherapy, and 75 to selective treatment in which treatment was not necessarily started immediately, but chemotherapy and, or, radiotherapy was given as and when required to control symptoms. With the policy of immediate compared with selective treatment, survival was longer (P less than 0.001, log-rank test), metastases were better controlled, and the quality of life as assessed intermittently by the clinicians was better, but there were more treatment-related deaths, adverse reactions were more common, reactions other than alopecia being reported in 80% compared with 33% (P less than 0.001) and the quality of life as reported daily by the patients using a diary card was worse.

Entities:  

Mesh:

Year:  1989        PMID: 2479963     DOI: 10.1016/s0954-6111(89)80060-5

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  8 in total

1.  Economic and quality-of-life aspects of treating small cell lung cancer.

Authors:  P Graham; J Boyages
Journal:  Pharmacoeconomics       Date:  1993-06       Impact factor: 4.981

2.  Quality-of-life assessment in small cell lung cancer.

Authors:  P Fayers
Journal:  Pharmacoeconomics       Date:  1992-09       Impact factor: 4.981

Review 3.  Quality of life measurement for patients undergoing treatment for lung cancer.

Authors:  R J Fergusson; A Cull
Journal:  Thorax       Date:  1991-09       Impact factor: 9.139

4.  Approaches to the analysis of quality of life data: experiences gained from a medical research council lung cancer working party palliative chemotherapy trial.

Authors:  P Hopwood; R J Stephens; D Machin
Journal:  Qual Life Res       Date:  1994-10       Impact factor: 4.147

Review 5.  Evaluation of quality of life for diverse patient populations.

Authors:  K R Yabroff; B P Linas; K Schulman
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 6.  MRC quality of life studies using a daily diary card--practical lessons learned from cancer trials.

Authors:  P Fayers
Journal:  Qual Life Res       Date:  1995-08       Impact factor: 4.147

7.  Women with lung cancer: impact on quality of life.

Authors:  L Sarna
Journal:  Qual Life Res       Date:  1993-02       Impact factor: 4.147

8.  Quality of life measurement in cancer patients receiving palliative radiotherapy for symptomatic lung cancer: a literature review.

Authors:  N Salvo; S Hadi; J Napolskikh; P Goh; E Sinclair; E Chow
Journal:  Curr Oncol       Date:  2009-03       Impact factor: 3.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.